In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
https://european-biotechnology.com/wp-content/uploads/2024/04/zynlonta_adc_therapeutics-web.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-07-11 12:10:002024-04-04 16:46:26Swedish SOBI awarded rights to market Zynlonta from ADC therapeutics
The European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused on bio-based production for products such as vitamins and other ingredients.
https://european-biotechnology.com/wp-content/uploads/2024/04/biosyntia-ecbf.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-07-08 10:43:512024-04-04 16:46:27ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in Biosyntia
Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.
https://european-biotechnology.com/wp-content/uploads/2024/04/Jan_van_den_Bossche_kl.jpg677602Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-07-08 09:52:062024-07-16 17:52:53Strengthening for Andera’s Life Sciences team
Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.
Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.
https://european-biotechnology.com/wp-content/uploads/2024/04/Lee_Patterson_CML_kl-scaled.jpg25602278Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-07-06 10:58:002024-07-16 17:54:15Charnwood Molecular with new CEO
French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2022-07-05_um_23.33.42.png8811297Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-07-05 17:10:002024-04-04 16:46:30Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.
Swedish SOBI awarded rights to market Zynlonta from ADC therapeutics
Latest NewsIn a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in Biosyntia
Latest NewsThe European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused on bio-based production for products such as vitamins and other ingredients.
Strengthening for Andera’s Life Sciences team
AppointmentsJan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.
Lonza invests CHF500m in Large-Scale Facility in Stein (CH)
Latest NewsLarge CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.
Charnwood Molecular with new CEO
AppointmentsLee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.
Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac
Latest NewsEvotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR).
Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
Latest NewsFrench drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.
CureVac NV sues BioNTech for IP infringement
Latest NewsGerman mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.
French Ipsen falls after Epizyme take-over announcement
Latest NewsShares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.
TWB announces winners in industrial biotech start-up contest
Latest NewsAt the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.